Philippe Berrouard | Brilliant Matters: Why is the industry-standard PEDOT:PSS failing the next generation of organic electronic devices?

Why is there such a massive performance gap between laboratory organic solar cells and roll-to-roll industrial production?

The scaling of Organic Photovoltaics (OPV) faces a significant bottleneck: the performance lag between sub-square-centimeter lab cells and large-scale industrial modules. While academic breakthroughs have rapidly pushed lab efficiencies upward, translating these achievements to roll-to-roll manufacturing introduces strict material and processing constraints. Industrial OPV demands highly pure, reproducible semiconductor batches produced at scale, where fine-chemical synthesis steps must be heavily optimized to minimize production costs.

Furthermore, industrial manufacturing cannot focus solely on power conversion efficiency. It requires a delicate trade-off between price, operating lifetime, and ink printability on flexible substrates. In a roll-to-roll setup, solvent dynamics, drying kinetics, and deposition tolerances limit the use of high-performing but volatile laboratory solvents, resulting in the observed industrial efficiency lag.

To close this gap, material design must pivot toward scalable, low-cost synthetic pathways. Brilliant Matters addresses this by engineering semiconducting polymers that maintain high purity and structural reproducibility even when scaled from sub-kilogram laboratory batches to industrial-grade volumes.

In this short video, you can learn:
* The primary chemical and synthetic causes of the lab-to-fab efficiency gap in organic photovoltaics.
* The complex trade-offs between efficiency, price, lifetime, and printability in industrial roll-to-roll processes.
* How high purity and batch-to-batch reproducibility impact semiconductor yield at scale.

📋 **Clip Abstract** This clip highlights the technical and economic barriers responsible for the performance lag between laboratory and industrial-scale organic solar cells. It details the material requirements, such as purity and synthetic scalability, necessary to transition OPV from a niche technology to roll-to-roll commercial reality.

How do you bridge the testing gap between spin-coated laboratory prototypes and industrial slot-die coaters?

Validating novel electronic inks for mass production requires a multi-stage translation pipeline. In laboratory environments, materials are initially screened using spin-coating on small-area substrates because of the rapid turnaround and minimal material consumption. However, spin-coating relies on centrifugal forces that do not mimic the shear rates or drying dynamics of industrial roll-to-roll systems.

To bridge this gap, the development process must transition to blade coating, which simulates the directional shear and wet-film deposition of slot-die coating on a benchtop scale. This step allows researchers to evaluate crucial ink properties such as film-forming capability, edge-pinning, and solvent evaporation kinetics before deploying formulations to manufacturing lines.

The final validation step involves sending optimized test batches to industrial printing partners. This collaboration yields real-world feedback on printability, ink-delivery line compatibility, and long-term fluid stability in commercial deposition heads, ensuring the synthetic material survives the transition to fab scale.

In this short video, you can learn:
* The distinct physical differences between laboratory spin-coating and industrial blade/slot-die coating dynamics.
* A multi-tier testing pipeline used to assess ink printability, film stability, and device morphology.
* The role of industrial printing partnerships in validating new materials for commercial-scale roll-to-roll runs.

📋 **Clip Abstract** This clip describes the systematic validation pipeline used to transition organic semiconductor inks from laboratory spin-coating to commercial roll-to-roll processes. It explains how benchtop blade coating and industrial partnership feedback loops mitigate scaling risks.